S
Kurt Graves
EVP, CCO, Head, Strategic Development, Vertex
MENTOR: David Brennan, former boss at Astra Merck, told him: "Find what's interesting and challenging and make a difference in the company."
LAUNCH STREAK: A record nine drugs in 18 months at Novartis
The rollout of Astra Merck came a full year earlier than planned. "We asked, 'How will we do this?'" remembers Kurt Graves. "Because it literally was a white sheet of paper." The only instructions from Merck CEO Roy Vagelos? "Go build America's 21st century pharma company."
Kurt Graves
Since those days, Graves hasn't stopped building—although the definition of a US pharma has evolved. At Astra Merck, he used blockbuster marketing to grow the flagship drug Prilosec, moving the company's sales from $150 million to $4 billion. As marketing chief of Novartis, he focused more on strategy. "Novartis was growing 4 percent—and 3.9 percent of it was price," says Graves. "Within a year, we completely changed the portfolio strategy, and repositioned and launched a lot of brands." From 2000–2004, Novartis was one of the fastest growing pharmas, with a 20 percent compound annual growth rate.
When Graves joined Vertex in July 2007, the model had yet again changed—and he was handed another blank slate on which to build a new model for a promising hep C drug. Graves seems up for the challenge: "To me, it's important to be part of a company that redefines what the industry will look like. We don't have a commercial model we have to fundamentally change. The beauty is that we get to build from scratch."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.